C50 C56 C54
Conditions
Interventions
Group 1: Breast Cancer Patients
- Blood draw
- Urine Analysis
- questionnaire
Group 2: Cancer free controls
Sponsors
Universitätsklinikum Heidelberg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: ? Age > 18 years ? Sufficient knowledge of the German language ? signed declaration of consent ? no physical or mental-psychological impairment ? Capacity to consent
Exclusion criteria
Exclusion criteria: ? Age < 18 years ? Missing signed declaration of consent ? Physical or mental-psychological impairment that makes it impossible to answer questionnaires ? Insufficient knowledge of the German language
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Development of a prediction model for breast cancer (compared to the gold standard). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. In addition, the following sub questions are to be answered: a. Are there tumor type-specific marker constellations? b. Do the additional, newly detected, blood-based, measurable markers have an added value to the marker constellation described so far and improve the algorithm? c. Is it possible to detect markers from urine as possible marker constellations? d. Which marker values distinguish other tumor diseases or other benign findings from BC disease? e. How are the markers to be detected in long-term survivors, i.e. women 5 years after cancer, without detectable current tumor manifestation? f. What are the marker signatures like in metastasized women? g. Which laboratory protocols can be established to simplify these measurements? h. How do the marker constellations in the blood differ from the expression in the tissue of the same patient? 2. Can our markers be measured in multiplex assays? 3. Evaluation of the possibility of predicting the long-term course of a breast cancer as well as the development of the biomarker composition in the long-term course on the basis of follow-up blood samples. 4. Secondary objective: asservation of blood and urine samples for the establishment of a biobank for further questions which may contribute to the optimization of the diagnosis and therapy of cancer. | — |
Countries
Germany
Contacts
Public ContactSarah Schott
Universitätsfrauenklinik
Outcome results
None listed